Publications published since 2010 from OUS - Section for Breast Oncology

238 publications found

Publications 2025

1. Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerød A, Lømo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Møller S et al. (2025)
   Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
   Clin Breast Cancer, 25 (6), e721-e730
   DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620
2. Johansen SH, Sæter M, Sarvari SI, Reinertsen KV, Edvardsen E, Wisløff T, Scott JM, Grydeland M, Raastad T, Hallén J, Kiserud CE, Lie HC, Solberg PA, Haugaa KH, Jensen JSS, Vatningen LH, Thorsen L, Nilsen TS (2025)
   Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors: A Randomized Controlled Trial
   JACC CardioOncol, 7 (4), 414-426
   DOI 10.1016/j.jaccao.2025.04.006, PubMed 40537190
3. Medhus A, Schink KO, Longva AS, Engebraaten O, Berg K, Weyergang A (2025)
   The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases
   Ther Adv Med Oncol, 17, 17588359251332473
   DOI 10.1177/17588359251332473, PubMed 40297622
4. Røssevold AH, Tekpli X, Lingjærde OC, Russnes HG, Vallon-Christersson J, Borgen E, Lømo J, Garred Ø, Dorraji E, Kristensen VN, Naume B, Kyte JA (2025)
   High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis
   Commun Med (Lond), 5 (1), 234
   DOI 10.1038/s43856-025-00865-z, PubMed 40523912
5. Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L (2025)
   Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
   Breast Cancer Res, 27 (1), 131
   DOI 10.1186/s13058-025-02082-x, PubMed 40660361
6. Sæter M, Johansen SH, Reinertsen KV, Thorsen L, Haugaa KH, Nilsen TS, Sarvari SI (2025)
   Cardiorespiratory fitness, cardiac morphology and function, and cardiovascular risk factors in long-term breast cancer survivors compared with non-cancer controls
   Cardiooncology, 11 (1), 1
   DOI 10.1186/s40959-024-00296-0, PubMed 39755716

Publications 2024

1. Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
   Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
   Mol Oncol, 19 (7), 2092-2108
   DOI 10.1002/1878-0261.13675, PubMed 38978352
2. Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
   Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
   J Immunother Cancer, 12 (1)
   DOI 10.1136/jitc-2023-007990, PubMed 38242720
3. Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V et al. (2024)
   Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
   J Clin Oncol, 42 (23), 2822-2832
   DOI 10.1200/JCO.23.02292, PubMed 38810178
4. Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
   Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
   NPJ Breast Cancer, 10 (1), 30
   DOI 10.1038/s41523-024-00638-2, PubMed 38653982
5. Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
   The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
   Br J Cancer, 131 (10), 1656-1667
   DOI 10.1038/s41416-024-02875-5, PubMed 39390250
6. Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
   An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
   Mol Oncol, 18 (8), 2042-2059
   DOI 10.1002/1878-0261.13656, PubMed 38671580
7. Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
   Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
   ESMO Open, 9 (6), 103475
   DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
8. Sharma A, Debik J, Naume B, Ohnstad HO, Oslo Breast Cancer Consortium (OSBREAC), Bathen TF, Giskeødegård GF (2024)
   Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes
   Oncogenesis, 13 (1), 22
   DOI 10.1038/s41389-024-00521-6, PubMed 38871719
9. Støyten M, Knutsen T, Stikbakke E, Agledahl I, Wilsgaard T, Eggen AE, Richardsen E, Giovannucci E, Thune I, Haugnes HS (2024)
   Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study
   Acta Oncol, 63, 154-163
   DOI 10.2340/1651-226X.2024.32953, PubMed 38591351
10. Svendsen K, Leithe S, Trewin-Nybråten CB, Balto A, Nes LS, Meland A, Børøsund E, Kiserud CE, Reinertsen KV, Eriksen HR, Gjelsvik YM, Ursin G (2024)
    How Did Breast Cancer Patients Fare during Different Phases of the COVID-19 Pandemic in Norway Compared to Age-Matched Controls?
    Cancers (Basel), 16 (3)
    DOI 10.3390/cancers16030602, PubMed 38339359
11. Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
    Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
    Mol Oncol, 19 (4), 1229-1243
    DOI 10.1002/1878-0261.13760, PubMed 39545921
12. Vandraas K, Reinertsen KV, Gudim HB, Bowen CA, Gjerdalen G, Schlichting E, Naume B, Sætersdal A (2024)
    [Not Available]
    Tidsskr Nor Laegeforen, 144 (12)
    DOI 10.4045/tidsskr.24.0182, PubMed 39404245

Publications 2023

1. Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A (2023)
   How I treat endocrine-dependent metastatic breast cancer
   ESMO Open, 8 (2), 100882
   DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375
2. Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
   Liver X receptors induce antiproliferative effects in basal-like breast cancer
   Mol Oncol, 17 (10), 2041-2055
   DOI 10.1002/1878-0261.13476, PubMed 37341140
3. Mikalsen SG, Skjøtskift T, Flote VG, Hämäläinen NP, Heydari M, Rydén-Eilertsen K (2023)
   Extensive clinical testing of Deep Learning Segmentation models for thorax and breast cancer radiotherapy planning
   Acta Oncol, 62 (10), 1184-1193
   DOI 10.1080/0284186X.2023.2270152, PubMed 37883678
4. Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
   MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
   Cancers (Basel), 15 (18)
   DOI 10.3390/cancers15184662, PubMed 37760629
5. Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
   High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
   PLoS One, 18 (1), e0280507
   DOI 10.1371/journal.pone.0280507, PubMed 36706086
6. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V et al. (2023)
   Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
   N Engl J Med, 388 (18), 1645-1656
   DOI 10.1056/NEJMoa2212856, PubMed 37133584
7. Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L (2023)
   Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
   Front Oncol, 13, 1040665
   DOI 10.3389/fonc.2023.1040665, PubMed 36910663
8. Riis ML, Augestad L, Flote VG, Tangerud A, Frich L (2023)
   Simultaneous cutaneous melanoma and ipsilateral breast cancer with metastasis to the same axilla. A case report with a focus on a multidisciplinary approach
   Int J Surg Case Rep, 114, 109119
   DOI 10.1016/j.ijscr.2023.109119, PubMed 38061088
9. Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE (2023)
   Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
   Breast Cancer Res Treat, 204 (2), 249-259
   DOI 10.1007/s10549-023-07147-z, PubMed 38123789
10. Svendsen K, Nes LS, Meland A, Larsson IM, Gjelsvik YM, Børøsund E, Rygg CM, Myklebust TÅ, Reinertsen KV, Kiserud CE, Skjerven H, Antoni MH, Chalder T, Mjaaland I, Carlson LE, Eriksen HR, Ursin G (2023)
    Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions
    JMIR Res Protoc, 12, e47195
    DOI 10.2196/47195, PubMed 37103493
11. Vandraas KF, Smedsland S, Engan HK, Kiserud C, Naume B, Brekke M, Reinertsen KV (2023)
    Late effects after breast cancer treatment
    Tidsskr Nor Laegeforen, 143 (11)
    DOI 10.4045/tidsskr.23.0017, PubMed 37589367
12. Åsberg RE, Nilsen M, Hjermstad MJ, Reinertsen KV, Karlsen J, Giskeødegård GF, Reidunsdatter RJ (2023)
    Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnaire QLQ-SHQ22 and the sexual domains of the QLQ-BR23/BR45
    Eur J Cancer, 190, 112943
    DOI 10.1016/j.ejca.2023.112943, PubMed 37515905

Publications 2022

1. Brunvoll SH, Flote VG, Halset EH, Bertheussen GF, Skjerven H, Lømo J, Thune I, Hjartåker A (2022)
   Normal and unusual days for dietary intake during the 12 months after a breast cancer diagnosis in women
   Eur J Nutr, 61 (8), 3873-3885
   DOI 10.1007/s00394-022-02925-9, PubMed 35750881
2. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
3. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
4. Lofterød T, Frydenberg H, Veierød MB, Jenum AK, Reitan JB, Wist EA, Thune I (2022)
   The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: The Oslo ethnic breast cancer study
   Acta Oncol, 61 (5), 649-657
   DOI 10.1080/0284186X.2022.2053573, PubMed 35348396
5. Merklinger-Gruchala A, Jasienska G, Thune I, Kapiszewska M (2022)
   Joint effect of particulate matter and cigarette smoke on women's sex hormones
   BMC Womens Health, 22 (1), 3
   DOI 10.1186/s12905-021-01586-w, PubMed 34996432
6. Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
   Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
   Cancers (Basel), 14 (5)
   DOI 10.3390/cancers14051326, PubMed 35267636
7. Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B (2022)
   Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
   BMC Cancer, 22 (1), 220
   DOI 10.1186/s12885-022-09306-9, PubMed 35227226
8. Rimstad R, Løkkevik E, Juul-Hansen KE, Holtan A (2022)
   Patient needs in evacuation of a tertiary oncology center
   J Emerg Manag, 20 (3), 267-272
   DOI 10.5055/jem.0626, PubMed 35792815
9. Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
   Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
   Nat Med, 28 (12), 2573-2583
   DOI 10.1038/s41591-022-02126-1, PubMed 36482103
10. Stalsberg R, Bertheussen GF, Børset H, Thomsen SN, Husøy A, Flote VG, Thune I, Lundgren S (2022)
    Do Breast Cancer Patients Manage to Participate in an Outdoor, Tailored, Physical Activity Program during Adjuvant Breast Cancer Treatment, Independent of Health and Socio-Demographic Characteristics?
    J Clin Med, 11 (3)
    DOI 10.3390/jcm11030843, PubMed 35160292
11. Stikbakke E, Wilsgaard T, Haugnes HS, Pedersen MI, Knutsen T, Støyten M, Giovannucci E, Eggen AE, Thune I, Richardsen E (2022)
    Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-life Study
    Cancers (Basel), 14 (5)
    DOI 10.3390/cancers14051142, PubMed 35267449
12. Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J (2022)
    RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
    NPJ Breast Cancer, 8 (1), 94
    DOI 10.1038/s41523-022-00465-3, PubMed 35974007
13. Svestad JG, Heydari M, Mikalsen SG, Flote VG, Nordby F, Hellebust TP (2022)
    Surface-guided positioning eliminates the need for skin markers in radiotherapy of right sided breast cancer: A single center randomized crossover trial
    Radiother Oncol, 177, 46-52
    DOI 10.1016/j.radonc.2022.10.017, PubMed 36309152
14. Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
    Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
    ESMO Open, 7 (5), 100588
    DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

1. Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L (2021)
   Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
   Mol Oncol, 15 (8), 2026-2045
   DOI 10.1002/1878-0261.12951, PubMed 33759347
2. Bøhn SK, Thune I, Flote VG, Frydenberg H, Bertheussen GF, Husøy A, Fjeldheim F, Brunvoll SH, Hjartåker A, Mowinckel MC, Sandset PM, Iversen PO (2021)
   Effects of a 1-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors: A Randomized Controlled Trial
   TH Open, 5 (1), e14-e23
   DOI 10.1055/s-0040-1721782, PubMed 33564742
3. Dahl AA, Kiserud CE, Fosså SD, Loge JH, Reinertsen KV, Ruud E, Lie HC (2021)
   A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study)
   Cancers (Basel), 13 (22)
   DOI 10.3390/cancers13225800, PubMed 34830953
4. Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A (2021)
   RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
   Nat Commun, 12 (1), 6427
   DOI 10.1038/s41467-021-26018-z, PubMed 34741021
5. Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M et al. (2021)
   Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
   Eur J Cancer, 154, 128-137
   DOI 10.1016/j.ejca.2021.06.028, PubMed 34265505
6. Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
   Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
   JCO Precis Oncol, 5
   DOI 10.1200/PO.20.00086, PubMed 34036235
7. Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, Naume B, Wiedswang G (2021)
   Preoperative CTC-Detection by CellSearch^® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer
   Cancers (Basel), 13 (3)
   DOI 10.3390/cancers13030485, PubMed 33513877
8. Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G (2021)
   In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
   Breast Cancer Res, 23 (1), 17
   DOI 10.1186/s13058-021-01393-z, PubMed 33526044
9. Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
   Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
   Sci Rep, 11 (1), 3388
   DOI 10.1038/s41598-021-81914-0, PubMed 33564016
10. Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, Osbreac OBO, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2021)
    Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
    Cancers (Basel), 13 (23)
    DOI 10.3390/cancers13236118, PubMed 34885228
11. Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J, Johnson J, Russnes HG, Bravo-Cordero JJ, Birbrair A, Naume B, Azhar M, Frenette PS, Aguirre-Ghiso JA (2021)
    Bone marrow NG2⁺/Nestin⁺ mesenchymal stem cells drive DTC dormancy via TGFβ2
    Nat Cancer, 2 (3), 327-339
    DOI 10.1038/s43018-021-00179-8, PubMed 34993493
12. Pandya AD, Iversen TG, Moestue S, Grinde MT, Mørch Ý, Snipstad S, Åslund AKO, Øy GF, Kildal W, Engebråten O, Sandvig K, Skotland T, Mælandsmo GM (2021)
    Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
    Nanomaterials (Basel), 11 (5)
    DOI 10.3390/nano11051140, PubMed 33924869
13. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F et al. (2021)
    Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
    Breast, 59, 327-338
    DOI 10.1016/j.breast.2021.07.021, PubMed 34390999
14. Stikbakke E, Schirmer H, Knutsen T, Støyten M, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Richardsen E, Thune I (2021)
    Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study
    Cancer Med, 11 (4), 1005-1015
    DOI 10.1002/cam4.4523, PubMed 34939344
15. Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
    Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
    Int J Cancer, 150 (1), 100-111
    DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

1. Brunvoll SH, Thune I, Bertheussen GF, Fjeldheim F, Flote VG, Frydenberg H, Lundgren S, Skjerven H, Lømo J, Fagerland MW, McTiernan A, Schlichting E, Hjartåker A (2020)
   Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery
   Br J Nutr, 125 (2), 172-182
   DOI 10.1017/S0007114520002627, PubMed 32811572
2. Frydenberg H, Harsem NK, Ofigsbø Å, Skoglund H, Brændengen M, Kaasa S, Guren MG (2020)
   Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
   Clin Colorectal Cancer, 19 (2), 141-144
   DOI 10.1016/j.clcc.2020.02.013, PubMed 32222353
3. Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H (2020)
   Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
   Mol Oncol, 15 (4), 957-967
   DOI 10.1002/1878-0261.12865, PubMed 33252186
4. Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G (2020)
   Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma
   Ann Surg, 271 (3), 549-558
   DOI 10.1097/SLA.0000000000003035, PubMed 30216219
5. Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
   ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
   J Transl Med, 18 (1), 269
   DOI 10.1186/s12967-020-02421-w, PubMed 32620163
6. Kyte JA, Røssevold A, Falk RS, Naume B (2020)
   ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
   J Transl Med, 18 (1), 252
   DOI 10.1186/s12967-020-02424-7, PubMed 32576225
7. Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, Akslen LA, Reitan JB, Wilsgaard T, Thune I (2020)
   Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study
   Breast Cancer Res Treat, 182 (1), 215-227
   DOI 10.1007/s10549-020-05679-2, PubMed 32436147
8. Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B (2020)
   Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
   BMC Cancer, 20 (1), 488
   DOI 10.1186/s12885-020-06979-y, PubMed 32473650
9. Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
   DNA copy number motifs are strong and independent predictors of survival in breast cancer
   Commun Biol, 3 (1), 153
   DOI 10.1038/s42003-020-0884-6, PubMed 32242091
10. von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
    Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
    Int J Cancer, 147 (9), 2515-2525
    DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

1. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
   Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
   Acta Oncol, 59 (4), 404-409
   DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
2. Dahl AA, Fosså SD, Lie HC, Loge JH, Reinertsen KV, Ruud E, Kiserud CE (2019)
   Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors
   J Adolesc Young Adult Oncol, 8 (3), 304-311
   DOI 10.1089/jayao.2018.0109, PubMed 30900929
3. Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
   Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
   J Proteome Res, 18 (10), 3649-3660
   DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
4. Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Naume B, Nygård JF (2019)
   Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry
   Int J Med Inform, 125, 102-109
   DOI 10.1016/j.ijmedinf.2019.03.004, PubMed 30914174
5. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
   Breast cancer quantitative proteome and proteogenomic landscape
   Nat Commun, 10 (1), 1600
   DOI 10.1038/s41467-019-09018-y, PubMed 30962452
6. Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
   Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
   Oncoimmunology, 8 (4), e1565236
   DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
7. Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
   Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
   Cancer Res, 79 (16), 4293-4304
   DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
8. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
   miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
   Mol Oncol, 13 (10), 2278-2296
   DOI 10.1002/1878-0261.12561, PubMed 31402562
9. Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, Skaaheim Haug E, Naume B, Møller B (2019)
   Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
   Cancer Epidemiol, 61, 59-69
   DOI 10.1016/j.canep.2019.05.004, PubMed 31153048
10. Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
    Int J Cancer, 146 (1), 223-235
    DOI 10.1002/ijc.32638, PubMed 31444972
11. Stikbakke E, Richardsen E, Knutsen T, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Thune I (2019)
    Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study
    Int J Cancer, 147 (1), 84-92
    DOI 10.1002/ijc.32718, PubMed 31583707
12. Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
    An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
    Nat Commun, 10 (1), 5499
    DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

1. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W et al. (2018)
   Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
   J Natl Cancer Inst, 110 (6), 560-567
   DOI 10.1093/jnci/djy018, PubMed 29659933
2. Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B (2018)
   NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
   Breast Cancer Res, 20 (1), 120
   DOI 10.1186/s13058-018-1049-0, PubMed 30322396
3. Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, Bjerve KS, Hjartåker A (2018)
   Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment
   Nutr J, 17 (1), 94
   DOI 10.1186/s12937-018-0402-6, PubMed 30333016
4. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
   Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
   Adv Radiat Oncol, 3 (2), 130-138
   DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
5. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
   Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
   Acta Oncol, 57 (9), 1225-1231
   DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
6. Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
   Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
   Genome Med, 10 (1), 92
   DOI 10.1186/s13073-018-0601-y, PubMed 30497530
7. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
   Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
   Oncoimmunology, 8 (2), e1537691
   DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
8. Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
   Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
   Oncoimmunology, 7 (11), e1457598
   DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
9. Lofterød T, Mortensen ES, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T, Eggen AE, McTiernan A, Aziz S, Wist EA, Stensvold A, Reitan JB, Akslen LA, Thune I (2018)
   Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes
   BMC Cancer, 18 (1), 654
   DOI 10.1186/s12885-018-4568-2, PubMed 29902993
10. Madssen TS, Thune I, Flote VG, Lundgren S, Bertheussen GF, Frydenberg H, Wist E, Schlichting E, Schäfer H, Fjøsne HE, Vettukattil R, Lømo J, Bathen TF, Giskeødegård GF (2018)
    Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment
    Br J Cancer, 119 (9), 1144-1154
    DOI 10.1038/s41416-018-0211-x, PubMed 30401977
11. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
    Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
    Cancer Immunol Res, 6 (4), 467-480
    DOI 10.1158/2326-6066.CIR-17-0207, PubMed 29459477
12. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
    Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
    Mol Oncol, 12 (9), 1540-1558
    DOI 10.1002/1878-0261.12319, PubMed 29741811
13. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
    Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
    Mol Oncol, 12 (11), 1838-1855
    DOI 10.1002/1878-0261.12375, PubMed 30133130
14. Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
    Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
    Cancer Lett, 439, 1-13
    DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

1. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
   Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
   Breast Cancer Res, 19 (1), 44
   DOI 10.1186/s13058-017-0812-y, PubMed 28356166
2. Bjørklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnæs GIG, Toppmeyer D, Riis M, Naume B, Børresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G (2017)
   Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
   Sci Rep, 7 (1), 5568
   DOI 10.1038/s41598-017-05537-0, PubMed 28717182
3. Broughton MN, Westgaard A, Paus E, Øijordsbakken M, Henanger KJ, Naume B, Bjøro T (2017)
   Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
   Tumour Biol, 39 (6), 1010428317707436
   DOI 10.1177/1010428317707436, PubMed 28653892
4. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
   Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
   Oncotarget, 8 (34), 57121-57133
   DOI 10.18632/oncotarget.19078, PubMed 28915659
5. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
   Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
   Breast Cancer Res Treat, 162 (1), 127-137
   DOI 10.1007/s10549-016-4096-1, PubMed 28058579
6. Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
   Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
   Metabolomics, 13 (4), 37
   DOI 10.1007/s11306-017-1168-0
7. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
   DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
   Oncotarget, 8 (1), 1074-1082
   DOI 10.18632/oncotarget.13718, PubMed 27911866
8. Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
   DNA methylation at enhancers identifies distinct breast cancer lineages
   Nat Commun, 8 (1), 1379
   DOI 10.1038/s41467-017-00510-x, PubMed 29123100
9. Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA (2017)
   Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
   J Natl Cancer Inst, 109 (8)
   DOI 10.1093/jnci/djw331, PubMed 28376188
10. Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017)
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
    Breast Cancer Res, 19 (1), 125
    DOI 10.1186/s13058-017-0916-4, PubMed 29183390
11. Juvet LK, Thune I, Elvsaas IKØ, Fors EA, Lundgren S, Bertheussen G, Leivseth G, Oldervoll LM (2017)
    The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta-analysis
    Breast, 33, 166-177
    DOI 10.1016/j.breast.2017.04.003, PubMed 28415013
12. Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
    Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
    Mol Imaging Biol, 19 (2), 271-279
    DOI 10.1007/s11307-016-0998-x, PubMed 27541026
13. Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Breast Cancer Res, 19 (1), 120
    DOI 10.1186/s13058-017-0911-9, PubMed 29137653
14. Reinertsen KV, Loge JH, Brekke M, Kiserud CE (2017)
    Chronic fatigue in adult cancer survivors
    Tidsskr. Nor. Laegeforen., 137 (21), 1701-1704
15. Reinertsen KV, Loge JH, Brekke M, Kiserud CE (2017)
    Chronic fatigue in adult cancer survivors
    Tidsskr Nor Laegeforen, 137 (21)
    DOI 10.4045/tidsskr.17.0040, PubMed 29135175
16. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
    Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
    Mol Oncol, 11 (10), 1361-1379
    DOI 10.1002/1878-0261.12105, PubMed 28657165
17. Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G (2017)
    Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
    Ann Surg Oncol, 24 (8), 2113-2121
    DOI 10.1245/s10434-017-5818-2, PubMed 28258416
18. Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
    The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
    Clin Cancer Res, 23 (16), 4662-4670
    DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
19. Vaysse C, Lomo J, Garred O, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husoy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
    Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer (vol 3, 35, 2017)
    npj Breast Cancer, 3, 35
    DOI 10.1038/s41523-017-0030-x
20. Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
    Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
    NPJ Breast Cancer, 3, 19
    DOI 10.1038/s41523-017-0015-9, PubMed 28649659
21. Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
    Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
    NPJ Breast Cancer, 3, 35
    DOI 10.1038/s41523-017-0030-x, PubMed 28884144

Publications 2016

1. Bandera EV, Fay SH, Giovannucci E, Leitzmann MF, Marklew R, McTiernan A, Mullee A, Romieu I, Thune I, Uauy R, Wiseman MJ, World Cancer Research Fund International Continuous Update Project Panel (2016)
   The use and interpretation of anthropometric measures in cancer epidemiology: A perspective from the world cancer research fund international continuous update project
   Int J Cancer, 139 (11), 2391-7
   DOI 10.1002/ijc.30248, PubMed 27352197
2. Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A (2016)
   Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
   Ecancermedicalscience, 10, 691
   DOI 10.3332/ecancer.2016.691, PubMed 27994647
3. Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B (2016)
   Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
   Genome Biol, 17 (1), 250
   DOI 10.1186/s13059-016-1109-7, PubMed 27931250
4. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin Transl Immunology, 5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
5. Fjeldheim FN, Frydenberg H, Flote VG, McTiernan A, Furberg AS, Ellison PT, Barrett ES, Wilsgaard T, Jasienska G, Ursin G, Wist EA, Thune I (2016)
   Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes
   BMC Cancer, 16 (1), 776
   DOI 10.1186/s12885-016-2804-1, PubMed 27717337
6. Flote VG, Vettukattil R, Bathen TF, Egeland T, McTiernan A, Frydenberg H, Husøy A, Finstad SE, Lømo J, Garred Ø, Schlichting E, Wist EA, Thune I (2016)
   Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer
   Lipids Health Dis, 15, 56
   DOI 10.1186/s12944-016-0225-4, PubMed 26970778
7. Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, Akslen LA, McTiernan A (2016)
   Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival
   Breast Cancer Res Treat, 155 (2), 345-54
   DOI 10.1007/s10549-015-3671-1, PubMed 26740213
8. Iversen A, Frydenberg H, Furberg AS, Flote VG, Finstad SE, McTiernan A, Ursin G, Wilsgaard T, Ellison PT, Jasienska G, Thune I (2016)
   Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women
   Eur J Cancer Prev, 25 (1), 9-18
   DOI 10.1097/CEJ.0000000000000130, PubMed 25714648
9. Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P (2016)
   Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
   Ann Oncol, 27 (9), 1719-25
   DOI 10.1093/annonc/mdw249, PubMed 27358383
10. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
    T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
    Oncoimmunology, 5 (12), e1249090
    DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
11. Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
    Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
    Oncoimmunology, 5 (11), e1232237
    DOI 10.1080/2162402X.2016.1232237, PubMed 27999747
12. Laake I, Larsen IK, Selmer R, Thune I, Veierød MB (2016)
    Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study
    BMC Cancer, 16, 402
    DOI 10.1186/s12885-016-2445-4, PubMed 27387027
13. Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE (2016)
    Fatigue During and After Breast Cancer Therapy-A Prospective Study
    J Pain Symptom Manage, 53 (3), 551-560
    DOI 10.1016/j.jpainsymman.2016.09.011, PubMed 28042070

Publications 2015

1. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
   Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
   Br J Cancer, 113 (11), 1548-55
   DOI 10.1038/bjc.2015.380, PubMed 26554649
2. Barrett ES, Chen C, Thurston SW, Haug LS, Sabaredzovic A, Fjeldheim FN, Frydenberg H, Lipson SF, Ellison PT, Thune I (2015)
   Perfluoroalkyl substances and ovarian hormone concentrations in naturally cycling women
   Fertil Steril, 103 (5), 1261-70.e3
   DOI 10.1016/j.fertnstert.2015.02.001, PubMed 25747128
3. Barrett ES, Tran V, Thurston SW, Frydenberg H, Lipson SF, Thune I, Ellison PT (2015)
   Women who are married or living as married have higher salivary estradiol and progesterone than unmarried women
   Am J Hum Biol, 27 (4), 501-7
   DOI 10.1002/ajhb.22676, PubMed 25753399
4. Bjørklund SS, Kristensen VN, Seiler M, Kumar S, Alnæs GI, Ming Y, Kerrigan J, Naume B, Sachidanandam R, Bhanot G, Børresen-Dale AL, Ganesan S (2015)
   Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
   BMC Cancer, 15, 524
   DOI 10.1186/s12885-015-1510-8, PubMed 26183823
5. Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjørnbeth BA, Borgen E, Naume B, Waage A, Wiedswang G (2015)
   Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases
   Ann Surg Oncol, 22 (12), 4029-37
   DOI 10.1245/s10434-015-4482-7, PubMed 25801354
6. Flote VG, Frydenberg H, Ursin G, Iversen A, Fagerland MW, Ellison PT, Wist EA, Egeland T, Wilsgaard T, McTiernan A, Furberg AS, Thune I (2015)
   High-density lipoprotein-cholesterol, daily estradiol and progesterone, and mammographic density phenotypes in premenopausal women
   Cancer Prev Res (Phila), 8 (6), 535-44
   DOI 10.1158/1940-6207.CAPR-14-0267, PubMed 25804612
7. Frydenberg H, Flote VG, Larsson IM, Barrett ES, Furberg AS, Ursin G, Wilsgaard T, Ellison PT, McTiernan A, Hjartåker A, Jasienska G, Thune I (2015)
   Alcohol consumption, endogenous estrogen and mammographic density among premenopausal women
   Breast Cancer Res, 17 (1), 103
   DOI 10.1186/s13058-015-0620-1, PubMed 26246001
8. Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
   Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
   Cancer Immunol Immunother, 64 (12), 1609-21
   DOI 10.1007/s00262-015-1766-5, PubMed 26498005
9. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
   Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
   Mol Oncol, 10 (1), 59-72
   DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
10. Jasienska G, Ellison PT, Galbarczyk A, Jasienski M, Kalemba-Drozdz M, Kapiszewska M, Nenko I, Thune I, Ziomkiewicz A (2015)
    Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: a case of antagonistic pleiotropy?
    Proc Biol Sci, 282 (1803), 20142395
    DOI 10.1098/rspb.2014.2395, PubMed 25673673
11. Klimek M, Galbarczyk A, Colleran H, Thune I, Ellison PT, Ziomkiewicz A, Jasienska G (2015)
    Digit ratio (2D:4D) does not correlate with daily 17β-estradiol and progesterone concentrations in healthy women of reproductive age
    Am J Hum Biol, 27 (5), 667-73
    DOI 10.1002/ajhb.22717, PubMed 25833729
12. Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE (2015)
    Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
    Mol Oncol, 9 (8), 1553-64
    DOI 10.1016/j.molonc.2015.04.008, PubMed 26004085
13. Marcinkowska UM, Ellison PT, Galbarczyk A, Milkowska K, Pawlowski B, Thune I, Jasienska G (2015)
    Lack of support for relation between woman's masculinity preference, estradiol level and mating context
    Horm Behav, 78, 1-7
    DOI 10.1016/j.yhbeh.2015.10.012, PubMed 26497247
14. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C (2015)
    Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
    Genes Dev, 29 (12), 1298-315
    DOI 10.1101/gad.263202.115, PubMed 26080815
15. Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015)
    Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival
    Ann Surg, 261 (1), 164-71
    DOI 10.1097/SLA.0000000000000580, PubMed 24509211
16. Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
    The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
    PLoS One, 10 (10), e0139965
    DOI 10.1371/journal.pone.0139965, PubMed 26460974

Publications 2014

1. Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014)
   Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
   Ann Oncol, 25 (10), 1901-1914
   DOI 10.1093/annonc/mdu042, PubMed 24769692
2. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014)
   A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
   Breast Cancer Res Treat, 145 (2), 411-8
   DOI 10.1007/s10549-014-2939-1, PubMed 24728613
3. Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2014)
   In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
   J Magn Reson Imaging, 41 (3), 601-9
   DOI 10.1002/jmri.24588, PubMed 24532410
4. Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Børresen-Dale AL, Kristensen VN, Tost J (2014)
   Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients
   Int J Cancer, 134 (11), 2615-25
   DOI 10.1002/ijc.28606, PubMed 24395279
5. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   Genome Biol, 15 (8), 435
   DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
6. Flote VG, Furberg AS, McTiernan A, Frydenberg H, Ursin G, Iversen A, Lofteroed T, Ellison PT, Wist EA, Egeland T, Wilsgaard T, Makar KW, Chang-Claude J, Thune I (2014)
   Gene variations in oestrogen pathways, CYP19A1, daily 17β-estradiol and mammographic density phenotypes in premenopausal women
   Breast Cancer Res, 16 (6), 499
   DOI 10.1186/s13058-014-0499-2, PubMed 25522654
7. Frydenberg H, Flote VG, Iversen A, Finstad SE, Furberg AS, Torjesen PA, Wilsgaard T, Schlichting E, Ellison PT, Ursin G, Thune I (2014)
   Insulin-like growth factor-1, growth hormone, and daily cycling estrogen are associated with mammographic density in premenopausal women
   Cancer Causes Control, 25 (7), 891-903
   DOI 10.1007/s10552-014-0389-z, PubMed 24801047
8. Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B (2014)
   Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
   BMC Cancer, 14, 514
   DOI 10.1186/1471-2407-14-514, PubMed 25023626
9. Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
   Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
   Breast Cancer Res, 16 (1), R5
   DOI 10.1186/bcr3597, PubMed 24447408
10. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
    Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
    Int J Cancer, 135 (9), 2085-95
    DOI 10.1002/ijc.28862, PubMed 24658971
11. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J et al. (2014)
    International study on inter-reader variability for circulating tumor cells in breast cancer
    Breast Cancer Res, 16 (2), R43
    DOI 10.1186/bcr3647, PubMed 24758318
12. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
    A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
    Clin Cancer Res, 21 (5), 1207-14
    DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
13. Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
    Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
    Acta Oncol, 53 (8), 1086-92
    DOI 10.3109/0284186X.2014.934398, PubMed 25017377
14. Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
    Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
    J Clin Oncol, 32 (34), 3848-57
    DOI 10.1200/JCO.2014.56.9327, PubMed 25366688
15. Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
    Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
    J Magn Reson Imaging, 40 (6), 1382-91
    DOI 10.1002/jmri.24502, PubMed 24470360
16. Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Sæter G, Jørgensen LH, Hall KS (2014)
    Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?
    Acta Oncol, 53 (9), 1180-7
    DOI 10.3109/0284186X.2014.899433, PubMed 24697744
17. Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Børresen-Dale AL, Hackermüller J, Baumbusch LO (2014)
    Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes
    PLoS One, 9 (9), e106076
    DOI 10.1371/journal.pone.0106076, PubMed 25264628
18. Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG (2014)
    Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
    Genes Chromosomes Cancer, 54 (4), 235-48
    DOI 10.1002/gcc.22237, PubMed 25546585
19. Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA (2014)
    Upper limb physical function and adverse effects after breast cancer surgery: a prospective 2.5-year follow-up study and preoperative measures
    Arch Phys Med Rehabil, 95 (5), 875-81
    DOI 10.1016/j.apmr.2013.12.015, PubMed 24389401
20. Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
    Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
    PLoS One, 9 (11), e113278
    DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

1. Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
   Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
   PLoS One, 8 (1), e53014
   DOI 10.1371/journal.pone.0053014, PubMed 23382830
2. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
   Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
   Int J Cancer, 134 (1), 102-13
   DOI 10.1002/ijc.28338, PubMed 23784959
3. Edvardsen H, Landmark-Høyvik H, Reinertsen KV, Zhao X, Grenaker-Alnæs GI, Nebdal D, Syvänen AC, Rødningen O, Alsner J, Overgaard J, Borresen-Dale AL, Fosså SD, Kristensen VN (2013)
   SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling
   Int J Radiat Oncol Biol Phys, 86 (4), 791-9
   DOI 10.1016/j.ijrobp.2013.02.025, PubMed 23597419
4. Engebraaten O, Vollan HKM, Børresen-Dale AL (2013)
   Triple-negative breast cancer and the need for new therapeutic targets
   Am J Pathol, 183 (4), 1064-1074
   DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
5. Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
   Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
   Magn Reson Med, 71 (6), 1973-81
   DOI 10.1002/mrm.24869, PubMed 23878023
6. Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
   Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
   Nucl Med Mol Imaging, 47 (3), 173-80
   DOI 10.1007/s13139-013-0211-y, PubMed 24900104
7. Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
   Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
   Acta Oncol, 52 (7), 1566-72
   DOI 10.3109/0284186X.2013.813634, PubMed 23984812
8. Kyte JA (2013)
   [The cancer riddle is outdated]
   Tidsskr Nor Laegeforen, 133 (18), 1907
   DOI 10.4045/tidsskr.13.1037, PubMed 24084948
9. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
   Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
   Clin Cancer Res, 20 (2), 404-12
   DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
10. Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
    The clinical impact of mean vessel size and solidity in breast carcinoma patients
    PLoS One, 8 (10), e75954
    DOI 10.1371/journal.pone.0075954, PubMed 24146798
11. Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
    Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
    J Magn Reson Imaging, 38 (5), 1043-53
    DOI 10.1002/jmri.24079, PubMed 23908122
12. Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN (2013)
    Next-generation sequencing of disseminated tumor cells
    Front Oncol, 3, 320
    DOI 10.3389/fonc.2013.00320, PubMed 24427740
13. Olsen K, Danielsen K, Wilsgaard T, Sangvik M, Sollid JU, Thune I, Eggen AE, Simonsen GS, Furberg AS (2013)
    Obesity and Staphylococcus aureus nasal colonization among women and men in a general population
    PLoS One, 8 (5), e63716
    DOI 10.1371/journal.pone.0063716, PubMed 23667661
14. Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B (2013)
    Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
    Breast Cancer Res Treat, 138 (2), 485-97
    DOI 10.1007/s10549-013-2439-8, PubMed 23456230
15. Tjessem KH, Johansen S, Malinen E, Reinertsen KV, Danielsen T, Fosså SD, Fosså A (2013)
    Long-term cardiac mortality after hypofractionated radiation therapy in breast cancer
    Int J Radiat Oncol Biol Phys, 87 (2), 337-43
    DOI 10.1016/j.ijrobp.2013.05.038, PubMed 23886416

Publications 2012

1. Barrett ES, Thune I, Lipson SF, Furberg AS, Ellison PT (2012)
   A factor analysis approach to examining relationships among ovarian steroid concentrations, gonadotrophin concentrations and menstrual cycle length characteristics in healthy, cycling women
   Hum Reprod, 28 (3), 801-11
   DOI 10.1093/humrep/des429, PubMed 23250924
2. Barrett ES, Tran V, Thurston S, Jasienska G, Furberg AS, Ellison PT, Thune I (2012)
   Marriage and motherhood are associated with lower testosterone concentrations in women
   Horm Behav, 63 (1), 72-9
   DOI 10.1016/j.yhbeh.2012.10.012, PubMed 23123222
3. Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
   Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
   Mol Oncol, 7 (1), 130-42
   DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
4. Bukowski R, Chlebowski RT, Thune I, Furberg AS, Hankins GD, Malone FD, D'Alton ME (2012)
   Birth weight, breast cancer and the potential mediating hormonal environment
   PLoS One, 7 (7), e40199
   DOI 10.1371/journal.pone.0040199, PubMed 22815728
5. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
   Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
   Histopathology, 61 (3), 350-64
   DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749
6. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
   Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
   Histol Histopathol, 27 (10), 1315-25
   DOI 10.14670/HH-27.1315, PubMed 22936450
7. Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
   Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
   ISRN Oncol, 2012, 176789
   DOI 10.5402/2012/176789, PubMed 22666610
8. Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
   Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
   PLoS One, 7 (9), e45492
   DOI 10.1371/journal.pone.0045492, PubMed 23029050
9. Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison PT, Jasienska G, Flote V, Poole EM, Furberg AS (2012)
   Genetic polymorphism CYP17 rs2486758 and metabolic risk factors predict daily salivary 17β-estradiol concentration in healthy premenopausal Norwegian women. The EBBA-I study
   J Clin Endocrinol Metab, 97 (5), E852-7
   DOI 10.1210/jc.2011-2577, PubMed 22419734
10. Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE (2012)
    Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
    Breast Cancer Res, 14 (2), R47
    DOI 10.1186/bcr3147, PubMed 22420423
11. Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
    MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
    PLoS One, 7 (4), e36263
    DOI 10.1371/journal.pone.0036263, PubMed 22558411
12. Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O (2012)
    Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
    Mol Oncol, 6 (4), 418-27
    DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242
13. Laake I, Carlsen MH, Pedersen JI, Weiderpass E, Selmer R, Kirkhus B, Thune I, Veierød MB (2012)
    Intake of trans fatty acids from partially hydrogenated vegetable and fish oils and ruminant fat in relation to cancer risk
    Int J Cancer, 132 (6), 1389-403
    DOI 10.1002/ijc.27737, PubMed 22821174
14. Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
    Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
    Breast Cancer Res, 14 (4), R117
    DOI 10.1186/bcr3242, PubMed 22889108
15. Molloy TJ, Roepman P, Naume B, van't Veer LJ (2012)
    A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients
    PLoS One, 7 (2), e32426
    DOI 10.1371/journal.pone.0032426, PubMed 22384245
16. Olsen K, Sangvik M, Simonsen GS, Sollid JU, Sundsfjord A, Thune I, Furberg AS (2012)
    Prevalence and population structure of Staphylococcus aureus nasal carriage in healthcare workers in a general population. The Tromsø Staph and Skin Study
    Epidemiol Infect, 141 (1), 143-52
    DOI 10.1017/S0950268812000465, PubMed 22440487
17. Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
    Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
    Acta Oncol, 52 (1), 91-101
    DOI 10.3109/0284186X.2012.713508, PubMed 22934555
18. Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
    Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
    BMC Cancer, 12, 616
    DOI 10.1186/1471-2407-12-616, PubMed 23259667
19. Tørris C, Thune I, Emaus A, Finstad SE, Bye A, Furberg AS, Barrett E, Jasienska G, Ellison P, Hjartåker A (2012)
    Duration of lactation, maternal metabolic profile, and body composition in the Norwegian EBBA I-study
    Breastfeed Med, 8 (1), 8-15
    DOI 10.1089/bfm.2012.0048, PubMed 23057641
20. Wist EA, Mjaaland I, Løkkevik E, Sommer HH (2012)
    Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
    J Oncol, 2012, 862921
    DOI 10.1155/2012/862921, PubMed 22291703
21. Ziomkiewicz A, Pawlowski B, Ellison PT, Lipson SF, Thune I, Jasienska G (2012)
    Higher luteal progesterone is associated with low levels of premenstrual aggressive behavior and fatigue
    Biol Psychol, 91 (3), 376-82
    DOI 10.1016/j.biopsycho.2012.08.001, PubMed 22906865

Publications 2011

1. Bernsdorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B (2011)
   Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
   Breast Cancer Res Treat, 126 (2), 463-70
   DOI 10.1007/s10549-011-1352-2, PubMed 21234672
2. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE (2011)
   Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel
   PLoS One, 6 (4), e19249
   DOI 10.1371/journal.pone.0019249, PubMed 21556366
3. Dahl AA, Nesvold IL, Reinertsen KV, Fosså SD (2011)
   Arm/shoulder problems and insomnia symptoms in breast cancer survivors: cross-sectional, controlled and longitudinal observations
   Sleep Med, 12 (6), 584-90
   DOI 10.1016/j.sleep.2011.01.011, PubMed 21645872
4. Emaus A, Thune I (2011)
   Physical activity and lung cancer prevention
   Recent Results Cancer Res, 186, 101-33
   DOI 10.1007/978-3-642-04231-7_5, PubMed 21113762
5. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
   miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
   PLoS One, 6 (2), e16915
   DOI 10.1371/journal.pone.0016915, PubMed 21364938
6. Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS (2011)
   13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
   NMR Biomed, 24 (10), 1243-52
   DOI 10.1002/nbm.1683, PubMed 21462378
7. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2011)
   In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
   J Magn Reson Imaging, 35 (5), 1098-107
   DOI 10.1002/jmri.23507, PubMed 22170753
8. Iversen A, Thune I, McTiernan A, Emaus A, Finstad SE, Flote V, Wilsgaard T, Lipson SF, Ellison PT, Jasienska G, Furberg AS (2011)
   Ovarian hormones and reproductive risk factors for breast cancer in premenopausal women: the Norwegian EBBA-I study
   Hum Reprod, 26 (6), 1519-29
   DOI 10.1093/humrep/der081, PubMed 21467202
9. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
   Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis
   Clin Cancer Res, 17 (9), 2967-76
   DOI 10.1158/1078-0432.CCR-10-2515, PubMed 21415211
10. Johansen S, Reinertsen KV, Knutstad K, Olsen DR, Fosså SD (2011)
    Dose distribution in the thyroid gland following radiation therapy of breast cancer--a retrospective study
    Radiat Oncol, 6, 68
    DOI 10.1186/1748-717X-6-68, PubMed 21651829
11. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
12. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
    Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
    Proc Natl Acad Sci U S A, 109 (8), 2802-7
    DOI 10.1073/pnas.1108781108, PubMed 21908711
13. Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2011)
    High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
    Int J Cancer, 131 (4), E405-15
    DOI 10.1002/ijc.26444, PubMed 21935921
14. Moestue SA, Engebraaten O, Gribbestad IS (2011)
    Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy
    Mol Oncol, 5 (3), 224-41
    DOI 10.1016/j.molonc.2011.04.001, PubMed 21536506
15. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
    The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
    Breast Cancer Res, 13 (3), R61
    DOI 10.1186/bcr2898, PubMed 21672237
16. Olsen K, Falch BM, Danielsen K, Johannessen M, Ericson Sollid JU, Thune I, Grimnes G, Jorde R, Simonsen GS, Furberg AS (2011)
    Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromsø Staph and Skin Study
    Eur J Clin Microbiol Infect Dis, 31 (4), 465-73
    DOI 10.1007/s10096-011-1331-x, PubMed 21811869
17. Orre IJ, Reinertsen KV, Aukrust P, Dahl AA, Fosså SD, Ueland T, Murison R (2011)
    Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors
    J Psychosom Res, 71 (3), 136-41
    DOI 10.1016/j.jpsychores.2011.04.003, PubMed 21843747
18. Reinertsen KV, Grenaker Alnæs GI, Landmark-Høyvik H, Loge JH, Wist E, Kristensen VN, Fosså SD, Edvardsen H (2011)
    Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway
    Brain Behav Immun, 25 (7), 1376-83
    DOI 10.1016/j.bbi.2011.04.001, PubMed 21496483
19. Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC (2011)
    Combining gene signatures improves prediction of breast cancer survival
    PLoS One, 6 (3), e17845
    DOI 10.1371/journal.pone.0017845, PubMed 21423775

Publications 2010

1. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2010)
   Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
   Breast Cancer Res Treat, 125 (3), 729-38
   DOI 10.1007/s10549-010-0911-2, PubMed 20449649
2. Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2010)
   Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
   Eur Radiol, 21 (6), 1188-99
   DOI 10.1007/s00330-010-2020-3, PubMed 21127880
3. Fors EA, Bertheussen GF, Thune I, Juvet LK, Elvsaas IK, Oldervoll L, Anker G, Falkmer U, Lundgren S, Leivseth G (2010)
   Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review
   Psychooncology, 20 (9), 909-18
   DOI 10.1002/pon.1844, PubMed 20821803
4. Fu YP, Edvardsen H, Kaushiva A, Arhancet JP, Howe TM, Kohaar I, Porter-Gill P, Shah A, Landmark-Høyvik H, Fosså SD, Ambs S, Naume B, Børresen-Dale AL, Kristensen VN, Prokunina-Olsson L (2010)
   NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations
   Mol Cancer, 9, 113
   DOI 10.1186/1476-4598-9-113, PubMed 20482849
5. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB (2010)
   DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables
   Mol Oncol, 5 (1), 77-92
   DOI 10.1016/j.molonc.2010.11.002, PubMed 21169070
6. Kyte JA (2010)
   Third International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD 2009)
   Expert Rev Vaccines, 9 (2), 119-23
   DOI 10.1586/erv.09.157, PubMed 20109021
7. Kyte JA (2010)
   [We know more than we can understand]
   Tidsskr Nor Laegeforen, 130 (22), 2217
   DOI 10.4045/tidsskr.10.1000, PubMed 21109831
8. Landmark-Høyvik H, Dumeaux V, Reinertsen KV, Edvardsen H, Fosså SD, Børresen-Dale AL (2010)
   Blood gene expression profiling of breast cancer survivors experiencing fibrosis
   Int J Radiat Oncol Biol Phys, 79 (3), 875-83
   DOI 10.1016/j.ijrobp.2010.09.052, PubMed 21129856
9. Landmark-Høyvik H, Reinertsen KV, Loge JH, Kristensen VN, Dumeaux V, Fosså SD, Børresen-Dale AL, Edvardsen H (2010)
   The genetics and epigenetics of fatigue
   PM R, 2 (5), 456-65
   DOI 10.1016/j.pmrj.2010.04.003, PubMed 20656628
10. Laake I, Thune I, Selmer R, Tretli S, Slattery ML, Veierød MB (2010)
    A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon
    Cancer Epidemiol Biomarkers Prev, 19 (6), 1511-22
    DOI 10.1158/1055-9965.EPI-09-0813, PubMed 20501754
11. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
    Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
    Mol. Oncol., 4 (2), 169
    DOI 10.1016/j.molonc.2010.01.003
12. Nesvold IL, Fosså SD, Holm I, Naume B, Dahl AA (2010)
    Arm/shoulder problems in breast cancer survivors are associated with reduced health and poorer physical quality of life
    Acta Oncol, 49 (3), 347-53
    DOI 10.3109/02841860903302905, PubMed 19842790
13. Nesvold IL, Reinertsen KV, Fosså SD, Dahl AA (2010)
    The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study
    J Cancer Surviv, 5 (1), 62-72
    DOI 10.1007/s11764-010-0156-4, PubMed 20972640
14. Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fosså SD (2010)
    Predictors and course of chronic fatigue in long-term breast cancer survivors
    J Cancer Surviv, 4 (4), 405-14
    DOI 10.1007/s11764-010-0145-7, PubMed 20862614
15. Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL (2010)
    Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
    Sci Transl Med, 2 (38), 38ra47
    DOI 10.1126/scitranslmed.3000611, PubMed 20592421
16. Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Børresen-Dale AL, Tost J, Kristensen V (2010)
    Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer
    Mol Oncol, 5 (1), 61-76
    DOI 10.1016/j.molonc.2010.11.004, PubMed 21212030
17. Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P (2010)
    Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
    J Clin Oncol, 28 (27), 4129-34
    DOI 10.1200/JCO.2009.26.4200, PubMed 20713855
18. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN (2010)
    Allele-specific copy number analysis of tumors
    Proc Natl Acad Sci U S A, 107 (39), 16910-5
    DOI 10.1073/pnas.1009843107, PubMed 20837533